Clinical Study of Chemotherapy Combined With Chinese Medicine on Survival Affect of Elderly Patients With Lung Cancer

Cancer Clinical Trial

Official title:

Randomized Double-blind Controlled Clinical Study of Chemotherapy Combined With or Without Traditional Chinese Medicine on Survival Affect of Elderly Patients With Advanced Non-small-cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01780181
• Other study ID #: 12401905700zzy
• Status: Completed
• Phase: N/A
• First received: January 29, 2013
• Last updated: October 14, 2016
• Start date: December 2012
• Est. completion date: September 2016

Study information

• Verified date: October 2016
• Source: Shanghai University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Science and Technology Commission of Shanghai Municipality
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to observe the efficacy of chemotherapy combined with Traditional Chinese Medicine for elderly patients with advanced non-small-cell lung cancer, also to evaluate the adverse reaction and the reliability.

Description:

Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer diagnoses and more than 75% of the patients are diagnosed with an advanced stage. ASCO guidelines recommended that elderly patients with advanced NSCLC use single-agent chemotherapy. Nearly a decade of clinical trials showed that:the median survival time (MST) of Vinorelbine is 5-10months,1-year survival rate is 32%;the MST of Gemcitabine is 6.8-9months,the MST of Taxol is 6.8-10.3months.Research had shown that TCM can prolong long-term survival and improve QOL, but high-level evidence is desperately needed to support this finding.

The investigators perform a multi-center, randomized, double-blind controlled, prospective study in elderly patients with advanced NSCLC. Patients are randomized over observational group (TCM granules plus single-agent chemotherapy), and control group (TCM placebo plus single-agent chemotherapy). The investigators will observe 4 cycles and after that regular follow-up will be arranged. The primary end point is: PFS (progression-free survival); the secondary end points are: (1) OS(overall survival); (2) Objective response rate; (3) TTP(Time-to-Progression); (4) QOL (EORTC QLQ-L43, TCM syndrome score); (5) other end points are: Toxicity, side effects and security of the treatments will be assessed at the same time. The investigators expect that integrated TCM combined with chemotherapy has a better efficacy on prolonging PFS, OS, improving QOL, reducing the adverse reaction of patients than that of chemotherapy.Therefore our study can provide evidences for optimizing and promoting integrated TCM combined with Western Medicine treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: September 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 65 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Pathologically or cytologically confirmed of stage IIIb-IV NSCLC ;

2. Ages Eligible for Study: =65 years old;

3. Physical status score (ECOG PS) = 2 scores;

4. Estimated life expectancy of at least 12 weeks;

5. Participants have no major organ dysfunction and chemotherapy contraindications:

hemoglobin =9g/dL, absolute neutrophil count (ANC) =1.5*109/L, platelets =100 *109/L,bilirubin=1.5ULN,alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 upper limited number(ULN) (AP, AST, ALT =5ULN is acceptable if liver has tumor involvement).INR=1.5, APTT in the normal range(1.2DLN-1.2ULN),creatinine=1.5ULN;

6. Informed consent from the patient.

Exclusion Criteria:

1. Patient with other malignant tumor except NSCLC 5 years previous to study entry.

2. Patients who have received single-agent chemotherapy treatment;

3. Estimated life expectancy less than 12 weeks;

4. Serious problem of heart, liver or kidney with severe dysfunction;

5. Pregnant or child breast feeding women;

6. Mental or cognitive disorders;

7. Participating in other drug trials;

8. Who are allergic to the study drug.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cancer
• Lung Neoplasms

Intervention

Drug:
• TCM
TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
• Chemotherapy
treated with single-agent chemotherapy :DOC?NVB?GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1,d8 Q3W GEM 1200mg/m2 d1,d8 Q3W

Locations

Country	Name	City	State
China	Zhiyi Zhou	Shanghai	Shanghai

Sponsors (3)

Lead Sponsor	Collaborator
Shanghai University of Traditional Chinese Medicine	Fudan University, Shanghai Chest Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival(PFS)		2 months	Yes
Secondary	overall survival		2 months	Yes
Secondary	Objective response rate		2 months	Yes
Secondary	Time-to-Progression(TTP)		2 months	Yes
Secondary	quality of life(QOL)		one cycle	Yes